XML 64 R48.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue (Disaggregation of Revenue by Product) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disaggregation of Revenue [Line Items]      
Revenues $ 28,541.4 $ 28,318.4 $ 24,539.8
U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 18,190.0 16,811.0 14,229.3
Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 10,351.3 11,507.4 10,310.5
Diabetes | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 9,911.1 8,719.3 7,909.1
Diabetes | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 4,553.7 4,468.8 3,925.3
Trulicity® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 5,688.8 4,914.4 3,835.9
Trulicity® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 1,750.9 1,557.6 1,232.2
Jardiance®      
Disaggregation of Revenue [Line Items]      
Revenues 2,066.0 1,490.8 1,153.8
Jardiance® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 1,194.5 807.3 620.8
Jardiance® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 871.5 683.5 533.0
Humalog® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 1,191.9 1,320.7 1,485.6
Humalog® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 868.7 1,132.3 1,140.3
Humulin® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 730.2 832.9 866.4
Humulin® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 289.2 389.6 393.2
Basaglar®      
Disaggregation of Revenue [Line Items]      
Revenues 760.4 892.5 1,124.4
Basaglar® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 470.7 588.3 842.3
Basaglar® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 289.7 304.2 282.1
Mounjaro® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 366.6 0.0 0.0
Mounjaro® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 115.9 0.0 0.0
Other diabetes | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 268.4 255.7 258.1
Other diabetes | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 367.8 401.6 344.5
Oncology | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 3,218.1 3,028.8 2,792.1
Oncology | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 2,448.1 2,712.5 2,527.2
Verzenio® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 1,653.2 834.9 618.2
Verzenio® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 830.3 515.0 294.4
Cyramza® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 351.4 358.1 381.9
Cyramza® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 620.0 674.8 650.8
Alimta® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 543.7 1,233.9 1,265.3
Alimta® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 384.0 827.5 1,064.7
Erbitux® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 500.1 481.8 480.1
Erbitux® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 66.4 66.4 56.3
Tyvyt®      
Disaggregation of Revenue [Line Items]      
Revenues 293.3 418.1 308.7
Tyvyt® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 0.0 0.0 0.0
Tyvyt® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 293.3 418.1 308.7
Other oncology | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 169.7 120.1 46.6
Other oncology | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 254.1 210.7 152.3
Immunology | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 1,892.8 1,881.8 1,372.3
Immunology | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 1,451.8 1,479.0 1,089.6
Taltz® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 1,724.6 1,542.4 1,288.5
Taltz® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 757.4 670.4 500.0
Olumiant®      
Disaggregation of Revenue [Line Items]      
Revenues 830.5 1,115.1 638.9
Olumiant® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 148.2 324.1 63.8
Olumiant® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 682.3 791.0 575.0
Other immunology | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 20.0 15.3 20.0
Other immunology | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 12.1 17.6 14.6
Neuroscience | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 612.4 614.8 487.3
Neuroscience | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 933.8 1,283.7 1,344.0
Emgality® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 462.8 434.5 325.9
Emgality® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 188.1 142.7 37.0
Zyprexa® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 30.4 39.6 46.1
Zyprexa® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 306.5 390.7 360.5
Cymbalta® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 33.7 38.7 42.1
Cymbalta® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 249.6 542.8 725.6
Other neuroscience | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 85.5 102.0 73.2
Other neuroscience | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 189.6 207.5 220.9
Other | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 2,555.7 2,566.4 1,668.4
Other | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 964.0 1,563.5 1,424.4
COVID-19 antibodies      
Disaggregation of Revenue [Line Items]      
Revenues 2,020.0 2,240.0 871.2
COVID-19 antibodies | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 2,008.9 1,978.0 850.0
COVID-19 antibodies | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 14.7 261.4 21.2
Forteo® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 367.3 441.6 510.3
Forteo® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 245.8 360.3 536.0
Cialis® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 35.2 10.6 61.8
Cialis® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 552.1 707.9 545.4
Other | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 144.2 136.1 246.4
Other | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues $ 151.3 $ 233.9 $ 321.8